Eric Richman

PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.

Part of American Bank, Inc., American Bank (Allentown, PA) is a financial institution that reflects the goals and aspirations of its customers. The company offers a range of products and services and provides personalized customer care. Mark W. Jaindl has been the CEO of the company since 1997.

ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ.

Tyrogenex, Inc. operates as a biopharmaceutical company which develops dual vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitors for wet age-related macular degeneration and solid tumors. Its compound targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. The company was founded by Chris Liang, Teri Ardleigh Swift, and Sheridan G. Snyder and is headquartered in Rockville, MD.

Labconnect Holdings, Inc. engages in providing laboratory services which include routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical. The company is headquartered in Seattle, WA.

Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA.

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

InFUSE Holdings, Inc. owns and operates ambulatory infusion centers. The company was founded by Timothy P. Johnson, Eric I. Richman, David M. Rothenberg, Gregory Gottschlich and is headquartered in Bethesda, MD.

Labconnect LLC provides global central laboratory services. It offers routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services. The company serves biopharmaceutical, medical device and contract research organizations. Labconnect was founded by Jeff Mayhew in 2002 and is headquartered in Seattle, WA.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.